Molecular profiling for precision cancer therapies.
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. · 2020
Read Molecular profiling for precision cancer therapies. by Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6961404.txt.
Introduction
Malone and co-authors review molecular profiling as the engine of precision cancer care. Their review appeared in Genome Medicine. The number of druggable, tumour-specific changes has grown sharply over the past decade. Matching drugs to markers already extends survival in several cancers. Profiling now informs diagnosis and prognosis too, not just drug choice.
Fast sequencing and large profiling programs have spread worldwide. Clinicians must then interpret complex results and act on them, which is the hard part. The authors survey current and upcoming approaches, plus newer layers beyond DNA: gene activity, immune profiles, chemical marks, and single-cell analysis. Liquid biopsies, which read tumour traces in blood, also feature. Lessons from the limits of gene-matched drugs, they argue, show how to widen precision medicine further.
Catalog record
| CREATOR | Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 102 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Molecular profiling for precision cancer therapies By Eoghan R. Malone, Marc Oliva, Peter J. B. Sabatini, Tracy L. Stockley, Lillian L. Siu Published in: Genome Medicine DOI: 10.1186/s13073-019-0703-1 ABSTRACT The number of druggable tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit obtained from biomarker matching therapies in several cancer types. Molecular pathology has therefore become fundamental not only to inform on tumor diagnosis and prognosis but also to drive therapeutic decisions in daily practice. The introduction of next-generation sequencing technologies and the rising number of large-scale tumor molecular profiling programs across institutions worldwide have revolutionized the field of precision oncology. As comprehensive genomic analyses become increasingly available in both clinical and research settings, healthcare professionals are faced with the complex tasks of result interpretation and translation. This review summarizes the current and upcoming approaches to implement precision cancer medicine, highlighting the challenges and potential solutions to facilitate the interpretation and to maximize the clinical utility of molecular profiling results. We describe novel molecular characterization strategies beyond tumor DNA sequencing, such as transcriptomics, immunophenotyping, epigenetic profiling, and single-cell analyses. We also review current and potential applications of liquid biopsies to evaluate blood-based biomarkers, such as circulating tumor cells and circulating nucleic acids. Last, lessons learned from the existing limitations of genotype-derived therapies provide insights into ways to expand precision medicine beyond genomics. BACKGROUND In the past decade, the field of oncology has witnessed substantial changes in the way patients with cancer are managed, with departure from a “one-size-fits-all” approach and increasing focus on precision medicine based on genomic variants. Cancer precision medicine is defined as “the use of therapeutics that are expected to confer benefit to a subset of patients whose cancer displays specific molecular or cellular features (most commonly genomic changes and changes in gene or protein expression patterns)” [1]. In certain tumors, molecular profiling may also yield clinically relevant diagnostic and prognostic information. Owing to the genomic complexity of cancers, precision medicine has been enabled by a growing body of knowledge that identifies key drivers of oncogenesis, coupled with advances in tumor analysis by next-generation sequencing (NGS) and other profiling technologies, and by the availability of new therapeutic agents. Precision medicine has already transformed cancer care: both common and rare malignancies can be targeted by specific therapies to improve clinical outcomes in patients (Table 1). This review focuses on current and emerging approaches, highlights successes and challenges, and proposes potential solutions in the implementation of precision medicine in clinical research and practice (Fig. 1). The expansion to other molecular characterization technologies beyond genomics, such as transcriptomics, epigenetics, and immunophenotyping, and to the evaluation of drug combinations beyond monotherapy approaches will hopefully increase the clinical utility and scope of precision medicine. Last, patients represent active key stakeholders in precision medicine initiatives; thus, resources must be deployed to optimize their education and engagement. Table 1FDA and EMA approved biomarker matching targeted drugs and routine molecular pathology testing [2, 3]Gene/proteinAnticancer agentIndicationsBiomarkerRoutine testingALKCrizotinib, ceritinib, alectinib, lorlatinib, brigatinibNSCLCALK translocationFISH, IHCAndrogen receptor (AR)Abiraterone, enzalutamide, dalurotamide, apalutamideProstate cancerAR expressionIHCBCL-2VenetoclaxChronic myeloid leukemiaBCL-2 protein expression, BCL-2 amplification/translocationIHC, FISHBCR/ABLImatinib, dasatinib, nilotinib, bosutinib, ponatinibChronic myeloid leukemiaBCR/ABL1 fusionIHC (FISH, DNA/RNA sequencing), PCR1BRAFDabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+binimetinibMelanoma, NSCLC, anaplastic thyroid cancer, hairy cell leukemiaBRAF V600E/K mutationsIHC, PCR1, DNA sequencingBRCAOlaparib, talazoparib, rucaparibBreast cancer, ovarian cancerGermline/somatic BRCA 1/2 mutationsDNA sequencingC-KIT, PDGFRImatinibGastrointestinal stromal tumorc-KIT Exon 9 and 11 mutations, PDGFR mutationsIHC, DNA sequencingPDGFRBImatinibMyelodysplastic/myeloproliferative syndromesPDGFRB rearrangementFISHEstrogen/progesterone receptors (ER/PR)Tamoxifen, raloxifene, fulvestrant, toremifineBreast cancerER/PR expressionIHCerBB2/HER-2Trastuzumab, pertuzumab, ado-trastuzumab, emtansine, neratinibBreast cancer, gastric cancerHER-2 protein expression, HER-2 amplificationIHC, FISHEGFRGefitinib, erlotinib, afatinib, dacomitinibNSCLCEGFR exon 19 deletion, exon 21 L858R mutationDNA sequencing, PCR1OsimertinibEGFR T790M mutationFGFR2/3ErdafitinibBladder cancerFGFR3 mutations, FGFR2/3 fusionsDNA sequencing, FISHFLT3Midostaurin, gilteritinibAcute myeloid leukemiaFLT3 mutationsDNA sequencing, PCR1IDH1/2Ivosidenib, enasidenibAcute myeloid leukemiaIDH1/2 mutationsIHC, DNA sequencingMETCrizotinib (breakthrough designation)NSCLCMET amplification, MET exon 14 alterationsFISH, DNA/RNA sequencingMSI-H or dMMRPembrolizumabMSI-H or dMMR solid tumorsMLH1, MSH2, MSH6, PMS2 protein expression, MSI highIHC, DNA sequencing, PCR1Nivolumab and ipilimumabColorectal cancerNTRKLarotrectinib, entrectinibSolid tumors with NTRK fusionsNTRK protein expression, NTRK fusionIHC, FISH, DNA/RNA sequencingPI3KCAAlpelisibBreast cancerPI3KCA mutationDNA sequencingPI3K (alpha and delta)CopanlisibFollicular lymphomaPI3K mutationDNA sequencingPI3K (delta and gamma)DuvelisibChronic lymphocytic leukemia, small lymphocytic lymphomaPI3K mutationDNA sequencingRAS (negative predictor)Cetuximab, panitumumabColorectal cancerKRAS/NRAS wildtypeDNA sequencingRETLOXO-292 (breakthrough designation)NSCLC, medullary thyroid cancerRET fusion, RET mutationFISH, DNA/RNA sequencingROS1Crizotinib, entrectinibNSCLCROS translocationFISH, DNA/RNA sequencingAR androgen receptor, dMMR deficient mismatch repair, ER estrogen receptor, FISH fluorescence in situ hybridization, IHC immunohistochemistry, MSI-H high levels of microsatellite instability, NSCLC non-small cell lung cancer, PR progesterone receptor1Applications of PCR may include fragment analysis, quantitative PCR, and restriction fragment length polymorphisms Fig. 1The process from genetic sequencing of patients to enrollment on genotype-matched clinical trials. MTB, molecular tumor board; IRB, institutional review board; NGS, next-generation sequencing CURRENT AND EMERGING MOLECULAR APPROACHES TO ENABLE PRECISION MEDICINE Integration of precision medicine with other diagnostic tests in clinical practice First and foremost, the important interactions between research and standard of care testing in precision cancer medicine must be highlighted. Large-scale research studies may identify new biomarkers with clinical utility, which can then be taken up as a new standard of care clinical diagnostic test to maximize the benefit to the patient population. Many tumor-specific molecular alterations, including protein overexpression, mutations in driver genes, or rearrangements, are well-proven predictive biomarkers of response to selective targeted therapies, with additional biomarkers rapidly emerging. Clinical molecular pathology analysis has therefore become an indispensable laboratory tool that can be used to characterize tumor biology and to drive therapeutic decisions. Conventional tests such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are fundamental precision medicine tools in daily practice [4], with many biomarkers currently detected by these two techniques (Table 1). IHC can detect changes at the protein level that result not only from gene aberrations, most commonly gene amplifications, but also from specific DNA rearrangements or point mutations (such as EML4-ALK translocation in non-small cell lung cancer (NSCLC) and IDH1/2 mutations in glioma) [5–7]. The use of IHC has extended to biomarkers of response to immuno-oncology (IO) agents, including PD-L1 expression or mismatch repair status, which determine the eligibility for therapies that are based on anti-PD-1/PD-L1 agents in certain tumor types [1, 4, 5, 8–10]. FISH has been the gold-standard technique for determining DNA rearrangements, and it is also routinely used to confirm amplifications at the gene level when IHC results are equivocal [11, 12]. As the number of druggable gene aberrations and predictive biomarkers grow in oncology, NGS technologies have increasingly substituted for conventional techniques, such as single-gene testing, and for targeted mutational platforms in routine molecular pathology. Conventional techniques have high sensitivity and specificity in detecting actionable mutations with proven benefit from matched targeted therapies or in identifying mutations that are associated with resistance to specific drugs [13–16]. However, with these techniques, each biomarker must be pre-specified in order to be detected and a purpose-made assay is required for each analyte. NGS can enable the simultaneous analysis of a broad spectrum of genomic alterations, including mutations, copy number variations (CNV), translocations, and fusions in multiple genes. It therefore provides a more efficient, cost- and tissue-saving tumor analysis as compared to serial single-biomarker analyses [17, 18], particularly in the context of the genomic complexity that is known to exist within tumors. Several studies comparing NGS performance against reverse transcriptase (RT)-PCR-based targeted mutation platforms, single-gene testing and other conventional techniques